On July 30, Alnylam Pharmaceuticals fell 7.45% in pre-market trading, trading at $265.31/share, with turnover of $1.0495 million. The decline occurred on the company's Q2 earnings release day amid elevated market expectations.

Consensus estimates ahead of the report called for revenue of approximately $1.32 billion, representing 70.56% year-over-year growth, and adjusted EPS of $1.59, up over 410% year-over-year. BofA Securities had previously noted that Q2 results would be critical in determining where full-year revenue falls within the $4.90 billion to $5.30 billion guidance range and whether management would refine that outlook. The firm also expressed concern over long-term Amvuttra net price erosion extending through 2031 due to competitive pressures, cutting its price target to $410 from $460 while maintaining a Buy rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)